Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin cardiovascular safety and renal outcomes study in high-risk type 2 diabetes
2011-004148-23Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Primary composite cardiovascular endpoint (4-point MACE). Started Jul 2013; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-004148-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004148-23.